2019/04/04 by Michiya Nishino, Jeffrey F. Krane, Jeffrey F. Krane · 1 citation
Medicine · #Biopsy #Cytology #Fine needle aspiration cytology #Fine-needle aspiration #Head and Neck Anomalies #Indeterminate #Internal medicine #Medicine #Pathology #Risk stratification #Thyroid #Thyroid Cancer Diagnosis and Treatment #Thyroid nodules
paper · doi:10.1159/000496502
crossref issued 2019/04/04 · crossref published 2019/04/04 · crossref published-online 2019/04/04 · openalex publication_date 2019/04/04 · crossref created 2019/04/04 · crossref published-print 2020/01/01 · crossref deposited 2025/04/23 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/30
Ancillary molecular testing has emerged as a promising way to refine the preoperative risk stratification of thyroid nodules with indeterminate fine needle aspiration (FNA) biopsy results. Commercially available molecular tests for thyroid FNAs include those that analyze samples for mutations and gene fusions, gene expression alterations, microRNA expression alterations, chromosomal copy number alterations, or a combination thereof. This review summarizes the performance characteristics of the most current iterations of three tests currently marketed for cytologically indeterminate thyroid nodules: ThyroSeq v3, ThyGeNEXT/ThyraMIR, and Afirma Gene Sequencing Classifier.